Verici has announced positive initial results from its validation study into its novel pre-transplant prognostic test Clarava. The test, which uses next-generation RNA sequencing, has proven to be an effective tool to help clinicians identify patients who are likely to experience a future transplant rejection ahead of their surgery. In order to enrich the utility data and support a statistically robust and clinically meaningful case for its commercial adoption, it will now enter an extended vali ....
